Success Metrics

Completion Rate
0%(0/1)
Active Trials
2(67%)
Terminated
1(33%)

Phase Distribution

Ph phase_2
1
33%
Ph phase_1
2
67%

Phase Distribution

2

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 2Efficacy & side effects
1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Terminated(1)

Detailed Status

Active, not recruiting1
Recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
2
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (66.7%)
Phase 21 (33.3%)

Trials by Status

active_not_recruiting133%
recruiting133%
terminated133%

Recent Activity

2 active trials
Showing 3 of 3
active_not_recruitingphase_2

Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies

NCT04925544
recruitingphase_1

A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)

NCT06789159
terminatedphase_1

Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC)

NCT03682055

Clinical Trials (3)

Showing 3 of 3 trials
NCT04925544Phase 2

Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies

Active Not Recruiting
NCT06789159Phase 1

A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)

Recruiting
NCT03682055Phase 1

Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC)

Terminated

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3